Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Deuterated drugs and biomarkers in the COVID-19 pandemic
ID
Jansen-van Vuuren, Ross D.
(
Avtor
),
ID
Jedlovčnik, Luka
(
Avtor
),
ID
Košmrlj, Janez
(
Avtor
),
ID
Massey, Thomas E.
(
Avtor
),
ID
Derdau, Volker
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(3,59 MB)
MD5: F23C1C6747856A5B6139D594A055AB73
URL - Izvorni URL, za dostop obiščite
https://pubs.acs.org/doi/10.1021/acsomega.2c04160
Galerija slik
Izvleček
Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan (China) in December 2019, COVID-19 rapidly spread globally, resulting in the COVID-19 pandemic. Carriers of the SARS-CoV-2 can experience symptoms ranging from mild to severe (or no symptoms whatsoever). Although vaccination provides extra immunity toward SARS-CoV-2, there has been an urgent need to develop treatments for COVID-19 to alleviate symptoms for carriers of the disease. In seeking a potential treatment, deuterated compounds have played a critical role either as therapeutic agents or as internal MS standards for studying the pharmacological properties of new drugs by quantifying the parent compounds and metabolites. We have identified >70 examples of deuterium-labeled compounds associated with treatment of COVID-19. Of these, we found 9 repurposed drugs and >20 novel drugs studied for potential therapeutic roles along with a total of 38 compounds (drugs, biomarkers, and lipids) explored as internal mass spectrometry standards. This review details the synthetic pathways and modes of action of these compounds (if known), and a brief analysis of each study.
Jezik:
Angleški jezik
Ključne besede:
COVID-19
,
hydrogen isotopes
,
inhibitors
,
metabolism
,
pharmaceuticals
Vrsta gradiva:
Članek v reviji
Tipologija:
1.02 - Pregledni znanstveni članek
Organizacija:
FKKT - Fakulteta za kemijo in kemijsko tehnologijo
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2022
Št. strani:
Str. 41840-41858
Številčenje:
Vol. 7, iss. 46
PID:
20.500.12556/RUL-144314
UDK:
547.8:546.11
ISSN pri članku:
2470-1343
DOI:
10.1021/acsomega.2c04160
COBISS.SI-ID:
131181827
Datum objave v RUL:
14.02.2023
Število ogledov:
587
Število prenosov:
446
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
ACS omega
Skrajšan naslov:
ACS omega
Založnik:
American Chemical Society
ISSN:
2470-1343
COBISS.SI-ID:
525873945
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
COVID-19
,
izotopi vodika
,
inhibitorji
,
presnova
,
zdravila
Projekti
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
Queen’s University, Rapid Response Funding
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
Southeastern Ontario Academic Medical Organization
Financer:
EC - European Commission
Program financ.:
H2020
Številka projekta:
945380
Naslov:
EUTOPIA-Science and Innovation Fellowships
Akronim:
EUTOPIA-SIF
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0230
Naslov:
Organska kemija: sinteza, struktura in aplikacija
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj